Novo pins obesity catch-up hopes on CagriSema against Eli Lilly
The cagrilintide-semaglutide combination is Novo's main lever to narrow Eli Lilly's lead in the obesity market.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 31 03:00 ETSource: Yahoo Finance
The wire
- 01The piece weighs whether CagriSema, Novo Nordisk's cagrilintide plus semaglutide combination, can close the competitive gap with Eli Lilly in obesity.
- 02Amylin-incretin combinations are the next wave clinicians and operators will have to position against tirzepatide and semaglutide.
- 03This is analysis rather than new trial data; commercial outcomes depend on label, pricing and launch timing not stated here.
From the source
Read at finance.yahoo.comCan CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?